DNA Diagnostics Market is Expected to Reach $19 Billion, Globally 2030


Posted April 18, 2022 by supriya

Global DNA diagnostics market is expected to garner $19 billion by 2020, registering a CAGR of 9.8% during the forecast period 2014-2020.
 
DNA Diagnostics Market by Product Type (Instruments, Reagents, Service & Software), Technology (PCR, Microarray, In-situ Hybridization, Sequencing Technology, Mass Spectrometry), Application (Infectious Disease (Hepatitis B Virus, Hepatitis C Virus, HIV, TB, CT/NG, HPV, MRSA), Myogenic Disorder, Prenatal Diagnostics, Pre-implantation Diagnostics) - Global Opportunity Analysis and Industry Forecast, 2013 - 2020

GET FREE SAMPLE @ https://www.alliedmarketresearch.com/request-sample/298
"Next generation sequencing not only reduces the cost of sequencing, but increases the throughput as well; it could thus help in bridging the gaps in traditional and personalized medications", adds the analyst. This makes it a promising investment opportunity for key players. Illumina Inc.'s new cost-effective genome machine HiSeq X Ten -the world's first DNA crunching supercomputer- is leading to a significant reduction in the price of sequencing a human genome.

Market analysis in terms of geography suggests that developed economies would retain their dominance in the market. This could be attributed to the early adoption of the technology due to potential reduction offered by DNA diagnostic to their high healthcare expenditure. However, developing economies, such as in Asia-Pacific, will significantly influence the DNA diagnostic market during the extended forecast period (2020-2025), largely due to potential growth in per capita healthcare expenditure and very large undiagnosed population.

Several companies operating in this region are seeking novel technologies to gain traction in the competitive market. Product launch is the key strategy adopted by companies operating in this market. These companies are developing novel products for the treatment of various diseases such as infectious diseases, cancer, prenatal diagnosis, pre-implantation diagnostics and myogenic disorder. Additionally, these companies are also adopting collaboration and acquisition to retain their respective positions and to gain traction in the market. Key companies profiled in the report are Bayer Diagnostic, Sysmex, Roche Diagnostics, Abbott laboratories, Cephide, Gene-probe Inc., Illumina, Inc., Thermo Fisher Scientific, Bio-Rad Laboratories, Johnson and Johnson, and Novartis.

READ MORE @ https://www.alliedmarketresearch.com/dna-diagnostics-market

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By AMR
Country India
Categories Blogging , Medical , Research
Tags dn adiagnostics , dn adiagnostics market , dn adiagnostics market size
Last Updated April 18, 2022